Melanoma Clinical Trial

Clinical Trial Finder Melanoma Trials

Study of Karenitecin (BNP1350) to Treat Malignant Melanoma

See Locations Near You

Summary

The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.

View Eligibility Criteria

Eligibility Criteria

Confirmed diagnosis of malignant melanoma
Measurable disease
Granulocytes ≥1,500/µl, Platelets ≥100,000/µl, Creatinine ≤ULN, Bilirubin ≤1.5 mg/dl, AST ≤2.5 x ULN
No prior treatment with other camptothecin drug.
≥ 21 days since completion of prior chemotherapy, ≥6 weeks since prior Mitomycin-C
ECOG Performance Status 0-1
Negative pregnancy test for female patients

Study is for people with:

Melanoma

Phase:

Phase 2

Estimated Enrollment:

46

Study ID:

NCT00062491

Recruitment Status:

Completed

Sponsor:

BioNumerik Pharmaceuticals, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

For Information call 210-614-1701 for a site near you
Tampa Florida, 33612, United States

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 2

Estimated Enrollment:

46

Study ID:

NCT00062491

Recruitment Status:

Completed

Sponsor:


BioNumerik Pharmaceuticals, Inc.

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider